RVNC Revance Therapeutics, Inc.

20.30
+0  (0%)
Previous Close 20.30
Open 20.50
Price To book 2.88
Market Cap 578.85M
Shares 28,515,000
Volume 143,531
Short Ratio 22.54
Av. Daily Volume 199,352

SEC filingsSee all SEC filings

  1. 8-K - Current report 17523862
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17522539
  3. 8-K - Current report 17511193
  4. 8-K - Current report 162046428
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161975286

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 full data due 1H 2017.
RT002
Cervical dystonia
Phase 3 data due 4Q 2017.
RT002 - SAKURA
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
  2. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Other Events
  3. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  4. Revance Provides Clinical Milestones and Financial Outlook for 2017
  5. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : December 15, 2016
  6. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : December 14, 2016
  7. REVANCE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
  8. Revance Announces Positive 24-Week Duration of Effect in Interim Results from Phase 2 Cervical Dystonia Trial
  9. Revance Announces Initiation of Subject Dosing in the SAKURA Phase 3 Clinical Program of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  10. ETFs with exposure to Revance Therapeutics, Inc. : December 2, 2016
  11. Coverage initiated on Revance Therapeutics by Aegis Capital
  12. Revance to Participate in the 28th Annual Piper Jaffray Healthcare Conference
  13. REVANCE THERAPEUTICS, INC. Financials
  14. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : November 10, 2016
  15. ETF’s with exposure to Revance Therapeutics, Inc. : November 8, 2016
  16. Revance to Participate in the Jefferies 2016 London Healthcare Conference
  17. Revance to Participate in the Jefferies 2016 London Healthcare Conference
  18. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
  19. REVANCE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  20. Edited Transcript of RVNC earnings conference call or presentation 3-Nov-16 8:30pm GMT

SEC Filings

  1. 8-K - Current report 17523862
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17522539
  3. 8-K - Current report 17511193
  4. 8-K - Current report 162046428
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161975286
  6. 8-K - Current report 161971796
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161811225
  8. 8-K - Current report 161808070
  9. CT ORDER - Confidential treatment order 161778203
  10. 8-K - Current report 161750684